Therapies for peripheral joint disease in psoriatic arthritis. A systematic review

Enrique R Soriano, Neil J McHugh

Research output: Contribution to journalArticlepeer-review

134 Citations (SciVal)


Traditional drug treatments for psoriatic arthritis (PsA) include nonsteroidal antiinflammatory agents (NSAID) and disease modifying antirheumatic drugs (DMARD), although the evidence base for their effectiveness is not well established. This review was compiled from a comprehensive literature search of electronic bibliographic databases for all English publications that were systematic reviews, metaanalyses, randomized controlled trials, controlled trials, and observational studies. The evidence supports NSAID for symptom relief, although data are lacking for COX-2-specific agents. No evidence exists to support systemic corticosteroids or corticosteroids by intraarticular injection, although the latter are commonly used in clinical practice. Among traditional DMARD, grade 1B evidence supports sulfasalazine, cyclosporine, and leflunomide for symptom relief, with lower-grade evidence for methotrexate. None of them slows radiographic progression. Grade 1B evidence supports improvement in symptoms, physical function, quality of life, and radiographic progression with anti-TNF antagonists (etanercept, infliximab, and adalimumab). The relative lack of evidence poses challenges in developing algorithms for treatment of peripheral arthritis in PsA.
Original languageEnglish
Pages (from-to)1422-1430
Number of pages9
JournalJournal of Rheumatology
Issue number7
Publication statusPublished - 2006


Dive into the research topics of 'Therapies for peripheral joint disease in psoriatic arthritis. A systematic review'. Together they form a unique fingerprint.

Cite this